Jasper Therapeutics secured approximately $132 million in gross proceeds from a recent PIPE financing to fund its operations through the second half of 2028. This Capital will support the advancement of its innovative therapies targeting immune-mediated diseases.

Key Highlights

  • Jasper Therapeutics completed an Acquisition of Kira Pharmaceuticals on July 16, enhancing its clinical portfolio.
  • Cash and equivalents totaled $7.3 million as of June 30, supporting ongoing development efforts.
  • With this capital injection, Jasper aims to advance its promising pipeline of therapies focused on immune-mediated diseases that present significant patient needs.

With this capital injection, Jasper aims to advance its promising pipeline of therapies focused on immune-mediated diseases that present significant patient needs. This financial backing is a important step for Jasper, paving the way for key development milestones in the upcoming quarters.

$132M PIPE Financing Completed

During this transaction on July 16, 2026, Jasper issued non-voting convertible preferred stock in a private placement, resulting in gross proceeds of approximately $132 million. This influx of capital is positioned to facilitate advancements in the company’s clinical pipeline, which includes therapies with applications in treating challenging immune-mediated diseases. Strong investor backing reflects confidence in the potential growth trajectory of the combined company’s assets.

Key Pipeline Developments

Jasper Therapeutics is actively progressing its combined portfolio targeting various immunologically-driven disorders. The company's lead asset, KP-104, is prepared for Phase 2/3 trials, targeting urgent needs in treating paroxysmal nocturnal hemoglobinuria and certain nephrology indications. Interim data from a Phase 2 basket trial is anticipated by the fourth quarter of 2026.

Accelerating the development of these innovative therapies is critical to address unmet medical needs and establish Jasper's presence as a leader in the field.

Recent Financial Outcomes

As of June 30, 2026, Jasper recorded a cash balance of $7.3 million, positioning the company to navigate upcoming operational demands. Research and Development expenses were reported at $5.1 million for the quarter, accompanied by general and administrative expenses of $4.1 million. These investments reflect ongoing commitments to advancing Clinical Trials and enhancing operational capabilities.

The net loss attributable to common stockholders stood at $2.8 million, equating to a loss per share of $0.10. Monitoring the utilization of resources allocated from the recent financing will be essential for assessing the company’s financial health in the near term.

Future Catalysts to Monitor

Jasper Therapeutics is gearing up for several significant milestones that could influence its clinical and financial progress. The expected interim data from the Phase 2 trials for KP-104 in rare renal indications will be disclosed in the fourth quarter of 2026. These developments, particularly in terms of regulatory interactions and trial progress, are critical for investor confidence and the company's long-term strategy in addressing severe immune-mediated diseases.